The total number of prevalent cases of primary prevention dyslipidemia in the Asia-Pacific countries under study will increase by 13% over the forecast period, from 272 million in 2016 to 308 million in 2026.
The total number of prevalent cases of secondary prevention dyslipidemia in the Asia-Pacific countries under study will increase by 26% over the forecast period, from 44 million in 2016 to 55 million in 2026.
Prevalence of Primary Prevention Dyslipidemia per 1,000 People Aged 20+ in 2016 and 2026
Relative Sizes of the Contributing Factors to the Trend in Prevalent Cases of Primary Prevention Dyslipidemia over the Next Ten Years
Prevalence of Secondary Prevention Dyslipidemia per 1,000 People Aged 20+ in 2016 and 2026
Relative Sizes of the Contributing Factors to the Trend in Prevalent Cases of Secondary Prevention Dyslipidemia over the Next Ten Years
Total Prevalent Cases of Dyslipidemia
Total Prevalent Cases of Primary and Secondary Prevention
Primary and Secondary Dyslipidemia Disease Definition
Studies Included in the Analysis of Dyslipidemia
Studies Excluded from the Analysis of Dyslipidemia
Risk/Protective Factors for Dyslipidemia
Ema Rodrigues, D.Sc., M.P.H.
Ema Rodrigues, D.Sc., M.P.H., is an epidemiologist with expertise in forecasting incident and prevalent populations in oncology and cardiovascular indications. She has significant experience with statistical methods such as multivariate linear regression, conditional logistic regression, principal components analysis, mixed models, hierarchical modeling, and path analysis to account for the complex relationships among various predictors of health outcomes, particularly correlated variables. She completed her master’s and doctoral degrees (M.P.H., D.Sc.) in environmental health at Boston University School of Public Health, where she worked on projects investigating significant predictors of various health outcomes, including central nervous system cancer, cognitive function, and birth outcomes.